37 results
8-K
ABSI
Absci Corp
27 Feb 24
Results of Operations and Financial Condition
4:45pm
and preserve the product’s identity, safety, strength, quality, and purity. The FDA may convene an advisory committee, typically a panel that includes … clinicians and other experts, to provide clinical insight on applications which present difficult questions of safety or efficacy and to review, evaluate
ARS
2024 FY
ABSI
Absci Corp
23 Apr 24
Annual report to shareholders
4:10pm
.......................................................................................................................... 78 Item 4. Mine Safety Disclosures … better safety profiles in patients. Hence, building large training data sets for biologic drugs interactions offers the potential for AI models
ARS
2022 FY
ABSI
Absci Corp
28 Apr 23
Annual report to shareholders
12:00am
4. Mine Safety Disclosures ................................................................................................................ 70 Part … and advance our DEIB efforts. We believe the more inclusive we are, the better our work will be. Health, safety, wellbeing: We are committed to promoting
424B5
dcsgx4p4mgpck
28 Feb 24
Prospectus supplement for primary offering
8:34am
424B5
kfw 1q9l9l
27 Feb 24
Prospectus supplement for primary offering
4:40pm
10-K
uc4 7d4anhycb
22 Mar 22
Annual report
5:20pm
424B4
1vh35herbyonc0
23 Jul 21
Prospectus supplement with pricing info
4:49pm
S-1/A
x1yb0 gb4v
8 Jul 21
IPO registration (amended)
5:04pm
S-1
tgtghh ux4yscub45
30 Jun 21
IPO registration
3:20pm
DRS/A
5u0j396
16 Jun 21
Draft registration statement (amended)
12:00am
DRS
gg7 64i4qje1x5
6 May 21
Draft registration statement
12:00am
8-K
EX-3.1
vltiy5lmkgxacvl2
16 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:07pm
10-Q
jv60xhhl 59h28plwtqi
7 Sep 21
Quarterly report
8:48am
S-1
EX-3.3
kosii h0t
30 Jun 21
IPO registration
3:20pm